Svenska
Boston
An independent LDT provider
Home
Press releases
Reports & Presentations
Stock information
Home
Stock information
Learn more
The Share
Stock information
The Share
Learn more
Share capital development
PDMR transactions
Ownership structure
Analysts
Governance
Home
Governance
Learn more
General meetings
Board of Directors
Management team
Governance report
Nomination committee
External auditors
Remuneration committee
Internal control
Articles of association
Sustainability Report
Rights issue 2023
Prospectuses
Home
Prospectuses
Learn more
Listing transfer (2018)
Rights Issue (2016)
Listing (2015)
Financial targets
Calendar
IR Contact
Home
IR Contact
Learn more
Subscribe
Subscribe
English
Svenska
NOTE:
Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:
https://rb.gy/09bxx
Press releases
Show
All
Regulatory
R = Regulatory
August 30, 2023
Immunovia Publishes Interim Report for January-June 2023
R
August 23, 2023
Invitation to Immunovia’s Q2 presentation
July 19, 2023
Immunovia announces updated financial calendar
July 11, 2023
Immunovia to Significantly Restructure to Focus Resources on its...
R
June 9, 2023
Chief Executive Officer, Jeff Borcherding, buys Immunovia shares
May 31, 2023
Change in number of shares and votes in Immunovia AB (publ)
R
May 26, 2023
Bulletin from the Annual General Meeting in Immunovia AB
R
May 23, 2023
Immunovia Publishes Interim Report for January-March 2023
R
May 22, 2023
Changes to the Nomination Committee’s proposal to the Annual...
R
May 17, 2023
Invitation to Immunovia’s Q1 presentation
May 6, 2023
The board member Philipp von Hugo resigns from Immunovia’s...
R
April 29, 2023
Immunovia AB appoints new CEO
R
1
2
3
…
7
>
Home
Archives for jonas.kaas
